Early-Phase Study to Assess Tumor Pharmacokinetics and Efficacy of the CDK4/6 Inhibitor Ribociclib (LEE011) in Patients With Recurrent Glioblastoma or Anaplastic Glioma
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2016
At a glance
- Drugs Ribociclib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 22 Mar 2016 Planned End Date changed from 1 Jul 2016 to 1 Jan 2018 as reported by ClinicalTrials.gov.
- 22 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Sep 2017 as reported by ClinicalTrials.gov.